Form D · Biotechnology
Dalix Therapeutics Inc
Valley Stream, NY · CIK 0001666562
Offering snapshot reported Feb 11, 2016 · SEC filing
- Reported sold
- $750K Offering amount: $6M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 26, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 11, 2016 | Initial | $750,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-257250
Source: Form D, filed Feb 11, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ran Alon | Executive |
| Yoram Drucker | Director, Executive |
| David Lubin | Executive |
| Leonard Sternherm | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O David Lubin & Associates 108 S Franklin Ave Ste 10
Valley Stream, NY, 11580
Valley Stream, NY, 11580